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Cyst Ablation Using a Mixture of N-Butyl
Cyanoacrylate and Iodized Oil in Patients
with Autosomal Dominant Polycystic
Kidney Disease: the Long-Term Results
Objective: We wanted to assess the long-term results of cyst ablation with
using N-butyl cyanoacrylate (NBCA) and iodized oil in patients with autosomal
dominant polycystic kidney disease (ADPKD) and symptomatic cysts.
Materials and Methods: Cyst ablation using a mixture of NBCA and iodized oil
was performed in 99 cysts from 21 patients who had such symptoms as abdomi-
nal distension and pain. The collapse or reaccumulation of the ablated cysts after
the procedure was assessed during the follow-up period of 36 to 90 months. The
treatment effects, including symptom relief, and the clinical data such as the
blood pressure and serum creatinine levels were also assessed, together with the
complications.
Results: The procedure was technically successful in all 99 cysts from the 21
patients. Any procedure-related significant complications were not detected.
Seventy-seven of 99 cysts (78%) were successfully collapsed on the follow-up
CT. Twenty-two cysts showed reaccumulation during long-term follow-up period.
The clinical symptoms were relieved in 17 of the 21 patients (76%). Four of 12
patients (33%) with hypertension and two of six patients (33%) with azotemia
were improved. End stage renal disease (ESRD) occurred in six of the 21
patients (28%) during the follow-up period. The mean age of ESRD in our
patients was 57 years. The mean time interval for the development of ESRD was
19 months.
Conclusion: Ablation using a mixture of NBCA and iodized oil may be an
effective, safe method for obtaining symptom relief in patients with ADPKD.
utosomal dominant polycystic kidney disease (ADPKD) is one of the
most frequent inherited disorders, and this is mainly characterized by
innumerable cysts in the both kidneys, with or without the presence of
cystic lesions in other organs (1-4). It is also the most frequent genetic cause of end
stage renal disease (ESRD) in adults (3-9). 
The progressive enlargement of renal cysts in ADPKD according to age can
frequently cause abdominal distension or pain, hypertension, infection and
hemorrhage of the urinary tract, nephrolithiasis and non-specific gastrointestinal
manifestations such as nausea. The most common complication of the patients with
ADPKD is abdominal distension or pain (10, 11). 
When medical analgesics fail to relieve abdominal distension or pain, then
decompressing procedures for the cysts may be necessary, including percutaneous
aspiration followed by instillation of sclerosing agents, or surgical treatments such as
laparoscopical decortication or marsupialization (12-16). The various sclerosing agents
have traditionally been used for the ablation of benign renal cysts and to prevent their
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Arecurrence. We have previously reported the successful
preliminary results of cyst ablation with using a mixture of
n-bultyl cyanoacrylate (NBCA) and iodized oil in ADPKD
patients.
The purpose of this study was to assess the long-term
results of cyst ablation with using a mixture of NBCA and
iodized oil, including the imaging and clinical data.
MATERIALS AND METHODS
Between October 1999 and March 2008, 21 ADPKD
patients with a total of 99 cysts were enrolled in this study.
The study groups consisted of nine men and 12 women
with a mean age of 51 years (age range: 33-78). We
retrospectively reviewed the radiologic findings and
medical records. The Institutional Review Board at our
hospital approved this study.
Two radiologists (each with 10 years experience with
various interventional genitourinary procedures) indepen-
dently performed cyst ablation for the patients with
ADPKD.
The treatment indications were as follow. All the patients
complained of abdominal distension and/or pain that was
caused by enlarged renal cysts, but none of them had
received previous surgical treatment. When the analgesics
failed to relieve the abdominal distension or pain, then cyst
ablation was tried. The size of the cysts was a mean of 5-6
cm in diameter. A cyst that caused irritation to the adjacent
peritoneum was also indicated for ablation. Twelve
patients had hypertension (i.e., a systolic/diastolic pressure
> 120/80 mmHg) and six patients had azotemia (i.e., an
increased serum creatinine level > 1.4 mg/dL). 
Because there was risk of leakage of the infected fluid or
blood from the cyst during procedure, the patients who
had acute symptoms such as cyst infection or bleeding
were excluded from this study. All the patients underwent
computed tomography (CT) for determining the indica-
tions and for targeting the cysts before the ablation. The
measured maximal diameter of the cysts before the
procedure was 3-10 cm (mean size: 6.5 cm).
Informed consent for the ablation was obtained for all
the cases. The procedures were performed with the patient
in either the prone or recumbent position after confirming
the location of the targeted cyst by using ultrasonographic
(US) guidance. After injection of local anesthesia, a 22-
gauge puncture needle was inserted into the targeted cyst.
The cystic fluid was aspirated as completely as possible and
the fluid volume was measured. 
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Table 1. Results of Cyst Ablation in 21 patients with Autosomal Dominant Polycystic Kidney Disease
Patient F/U F/U
Numbers  Creatinine Level  Blood Pressure  ESRD 
(Age/ Periods  CT
of  Symptom  (mg/dL) (Systolic/Diastolic mmHg) (Age/
Gender) (Mo) Numbers 
Ablated  Improvement Before  After  Before  After  Time 
Cysts Ablation  Ablation Ablation  Ablation Interval) 
36/F 60 2 5 Yes 1.1  1.0 110/80  120/80 No
52/M  50 2 3 Yes 1.2  3.4 130/90  140/100 Yes (54/23 Mo)
47/M 36 1 5 Yes 1.0  0.9  110/70  110/80 No
78/F 38 1 4 No 1.2  1.0 120/80  120/80 No
43/F 90 3 6 Yes 1.0  1.1 150/90  120/80 No
33/F 71 3 5 Yes 1.1  1.2  100/70  110/80 No
47/M 62 2 4 Yes 2.1  1.0 120/70  130/80 No
66/F 58 2 5 No 1.7  2.8 140/90  150/100 Yes (68/18 Mo)
46/M 85 3 5 Yes 0.9  0.8 100/70  110/80 No
51/F 53 2 4 Yes 1.2  1.1 150/100  130/80 No
40/F 39 1 5 Yes 1.6  1.0 150/90  125/85 No
59/M 81 3 4 Yes  1.7  3.0  130/85  150/95 Yes (61/15 Mo)
49/M 49 2 5 Yes 1.1  1.2 145/95  125/80 No
53/M 52 3 4 Yes  1.7  2.3  140/85  145/95 Yes (56/24 Mo)
41/F 59 3 4 Yes  1.3  1.2 135/95  130/90 No
37/M 55 3 5 Yes 1.0  0.9 115/80  120/80 No
53/F 58 2 4  No 1.5  2.7 120/90  140/95  Yes (55/21 Mo)
47/F 42 2 6 No 1.1  1.3 120/80  110/80 No
61/F 52 2 5 Yes  1.3  2.0  140/100  155/100 No
54/F 46 3 5 Yes 0.9  0.8 130/90  130/95 No
61/M 40 2 6 No  1.3  2.5 130/90  145/95 Yes (63/16 Mo)
Note.─ F/U = follow up, ESRD = end stage renal disease, Mo = months, time interval = duration between initial cyst ablation and presence of ESRDAfter injection of 0.3 mL of 5% dextrose water, a
mixture of 0.5 mL of NBCA and 1 mL of iodized oil (a
ratio of 1:2) was injected regardless of the volume of the
aspirated fluid. The plain radiograph was then obtained to
ensure whether the injected materials were confined within
the cyst. Then the same procedure was performed for the
next cyst. The number of cyst ablations at a single session
in a patient ranged from three to six. 
The average follow-up period was 54 months (range: 36-
90). Follow-up CT was performed for all the patients. The
average time interval between the ablation and the first CT
follow-up was at 36-80 months (mean interval: 45.3
months). CT follow-up was performed one to three times
for each patient (mean: 2.3). CT follow-up was performed
two times for 11 patients and three times for eight patients. 
We assessed the rates of technical success and the
immediate complications of the procedure. Technical
success was regarded as obtainment of a collapsed cyst
with opacity that represented the mixture of NBCA and
iodized oil.
To analyze the long term results, we assessed the follow-
up CT findings and we compared the clinical data of the
patients. We categorized the long term results into total
collapse, partial collapse and reaccumulation. We regarded
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Fig. 1. 36-year-old woman with autosomal dominant polycystic kidney disease.
A, B. Axial contrast enhanced CT scans show multiple cysts in both kidneys. Cyst ablation was performed for two cysts in right kidney
and for two cysts in left kidney (asterisk).
C, D. Antero-posterior radiographies after procedure show lobulated radiopacities that represent mixture of N-butyl cyanoacrylate and
iodized oil in right (C) and left (D) kidneys.
CDas total collapse as < 10% volume of the initial volume,
partial collapse as 10-50% volume of the initial volume
and reaccumulation as > 10% volume of the initial volume
or wash-out of the mixture of NBCA and iodized oil. Early
reaccumulation was regarded as a collection of fluid in the
ablated cyst on the first follow-up CT, and delayed reaccu-
mulation was regarded as a collection of fluid in the
ablated cyst on the second and third follow-up CTs.
We assessed the clinical relief of symptoms and the long
term change of the clinical data of the patients, including
the blood pressure and the serum creatinine levels. The
rate of ESRD and the age this occurred were also assessed.
RESULTS
The volume of aspirated cystic fluid ranged from 10 to
300 mL (mean volume: 61 mL). The procedure was techni-
cally successful for all 99 cysts of the 21 patients. For nine
cysts of four patients, two sessions of ablations were
performed for the subsequent reduction of the cystic
volume. On the radiograph obtained after the procedures,
the radiopacity of the mixture of NBCA and iodized oil
was correctly confined within all the injected cysts, without
leakage to other organs. The eight patients complained
mild pain immediately after the procedure. Any significant
complications related to the procedures were not found. 
The results of cyst ablation in this study are summarized
in Table 1. During the follow-up period, 77 of 99 cysts
(78%) were successfully ablated (Fig. 1) without reaccumu-
lation of fluid. Forty-five of 77 cysts (58%) were totally
collapsed and 32 cysts (42%) were partially collapsed.
Eight of 99 cysts (8%) showed-up CT reaccumulation of
fluid on the first follow-up CT, and 14 of 99 cysts (14%)
showed delayed reaccumulation on the second and third
follow-up CTs (Fig. 2). For the cysts that totally or partially
collapsed, the mean diameter of the radiopacities that
represent the mixture of NBCA and iodized oil was 2.3
cm. The mean diameter of the cysts with reaccumulation
was 5.9 cm.
In 17 of 21 patients (76%), the symptoms such as
abdominal distension or pain were relieved, while in the
remaining four patients, their symptoms were not relieved
or they were aggravated after the procedure. The effect of
symptom relief was prolonged for 26 to 50 months (mean:
28.5).
All 12 patients with hypertension underwent medical
treatment. Four of the 12 patients (33%) with hyperten-
sion became normotensive after the procedure, and this
was prolonged for at least 36 months. Two of the six
patients (33%) with azotemia had their serum creatinine
level drop to the normal range, and this was prolonged for
at least 19 months. ESRD occurred in six of 21 patients
(28%) and this led to dialysis during the follow-up period.
The mean age for the occurrence of ESRD in our patients
was 57 years (age range: 52-66). The mean time interval
between the initial cyst ablation and the presence of ESRD
was 19 months (range: 15-24).
DISCUSSION
For the reduction of the cystic volume and to prevent
cyst recurrence, ablation by instillation of sclerosing agents
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Fig. 1. 36-year-old woman with autosomal dominant polycystic kidney disease.
E. Follow-up CT scans 36 months after procedure show collapsed cysts with mixture of N-butyl cyanoacrylate and iodized oil.
F. Follow-up CT scans at 60 months show no evidence of reaccumulation in ablated cysts.
EFcan be effectively used to destroy the cyst wall epithelium
(17-19). Several agents have been used for this, including
absolute ethanol, minocycline hydrochloride, povidone-
iodine, acetic acid, ethanolamine oleate and holmium-166-
chitosan complex. Of these various sclerosing agents,
absolute ethanol is most commonly used (20-27). Absolute
ethanol has generally been used as a safe and effective
sclerosing agent in benign renal cysts. However, ablation
by absolute ethanol instillation through a catheter is associ-
ated with various complications, including pain, fever and
systemic reactions such as drunkenness and shock (25-27).
Especially, the application of absolute ethanol ablation is
not easy in symptomatic patients with ADPKD because of
the presence of multiple large cysts and the difficulty in
identifying the cysts that are associated with symptoms
(26, 27). Inserting the catheter into many cysts for ethanol
ablation is not easy and this may make the patient
uncomfortable, and ethanol ablation of a renal cyst usually
takes several days (27).
N-butyl cyanoacrylate has recently been used for the
embolization of vascular lesions in various parts of the
body and for endoscopic management of bleeding and
fistula (28). In contrast with absolute ethanol ablation, this
procedure is simple without catheter insertion and this can
be performed for multiple cysts in a single session.
No significant complications related with procedures
using NBCA have been reported. Leakage of NBCA does
not occur because of the immediate conversion of
polymerize NBCA into a solid substance in ionic solutions
such as tissue fluid and blood (27, 29).
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Fig. 2. 52-year-old man with autosomal dominant polycystic kidney disease and who underwent cyst ablation.
A, B. Follow-up CT scans 24 month later show radiopacities within ablated cysts.
C, D. Follow-up CT scans at 50 month show reaccumulation of cystic fluid. 
CDKim et al. (29) reported that percutaneous needle aspira-
tion and intracystic injection of a mixture of NBCA with
iodized oil were effective in reducing the volume of cysts
and obtaining symptom relief in patients with ADPKD.
However, that previous study had some limitations such
that the reaccumulation of fluid in ablated cysts, the
duration of symptom relief and the changes of such clinical
data as the blood pressure and the serum creatinine level
were not assessed on long-term follow-up. 
Our study had a 100% technical success rate. Seventy-
eight percent of the cysts were totally or partially collapsed
without reaccumulation of fluid during the long term
follow-up. In our study, the success rate was similar to the
success rate for those patients who underwent ablation
using absolute ethanol or other sclerosing agents for
treating large simple renal cysts in other reports (25-27).
The mixture of NBCA and iodized oil fixed the epithelial
lining cells and caused permanent obliteration of the cyst
lining.
Reaccumulation of the cystic fluid occurred in 22% of
the ablated cysts. The reaccumulation rate was lower
compared with the recurrence rate (32%) for ablation with
using absolute ethanol in a two-year follow-up study (27).
Reaccumulation usually occurred in large cysts and this
might have been caused by the incomplete aspiration of
the cystic fluid and the small amount of NBCA to cover
the total area of the cyst epithelium. To avoid this, the
needle tip should be monitored with US so that it remains
in the center of the cyst during aspiration. Once the cyst
fluid has been completely aspirated with a 10-mL syringe,
we performed further repeated aspiration with using a 2-
mL syringe. Nevertheless, ablation with using a mixture of
NBCA and iodized oil might collapse almost all the large
cysts in a single session without reaccumulation.
The symptoms were relieved in 76% of the patients
during the follow-up period. The duration of subjective
symptom relief was a mean of 28.5 months for 17 patients.
Lee and Lee (27) reported that the probability of being
pain free one year after absolute ethanol ablation was
64%, and this was in line with the results of our study.
Although the patients’ other cysts gradually grew, the
symptoms did not develop again after ablation of the
largest symptomatic cysts. Thus, selective cyst ablation
may be an effective method for managing abdominal
distension or pain in patients with ADPKD.
After the procedure, the four patients with hypertension
and the two patients with azotemia were improved during
more than 36 months follow-up. However the renal
function of six patients, including four patients whose
symptoms were relieved after the cyst ablation, decreased
gradually and this resulted in ESRD during the follow-up
period. 
The development to ESRD has been shown to be highly
variable in patients with ADPKD. In most patients, the
renal function is maintained within the normal ranges,
despite of the progressive growth of cysts, until the fourth
to six decade of life (1-3). The average age and rate of
development to ESRD in our study were not so different
from the mean age and rate of developing to ESRD in
untreated patients (3). Several studies have reported that
patients with radiographically identifiable ADPKD have a
2% chance of developing ESRD by the age of 40 years, a
23% chance by the age of 50 and a 48% chance by the age
of 73 (2, 3). Several studies have also shown that the
kidney and cyst volumes are the strong predictors of renal
function decline (1, 3). In all our patients with ESRD, other
innumerable cysts were progressively increased in size,
without regard to the collapse or reaccumulation of the
ablated cysts. This study revealed only a limited effect of
cyst ablation to prevent ESRD in patients with ADPKD.
However we think that cyst ablation may be more
effective to prevent ESRD if it is performed in the early
stage of the ADPKD in a patient with only several large
cysts.
This study had several limitations. This was a retrospec-
tive study and the image follow-up was not performed
according to a regular time interval and protocol.
Comparison of the clinical data of our patients with those
of a control group was not performed. The indication
criteria for cyst ablation were not well established. We
could not analyze the results according to the extent and
severity of ADPKD, which might have affected the clinical
data in this study. We did not perform repeated cyst
ablation for the treatment of any patients with recurrent
hypertension or azotemia.
Despite the several limitations of this study, we believe
that cyst ablation with using a mixture of NBCA and
iodized oil may be a useful and safe method to obtain
symptomatic relief in patients with ADPKD. 
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